When Thyme Care announced its Series E in September 2026, the headline number was $125 million. The more telling figure was the one that came with it: a valuation north of $2 billion. That is roughly double what the company was worth less than 12 months ago, when it closed its Series D. In a venture market that has been largely unforgiving to health tech since 2022, that kind of trajectory stands out.
Thyme Care is not a hospital. It is not a clinic. It does not own imaging equipment or employ oncologists under its own brand. What it does is navigate cancer patients through the existing care system - helping them understand their diagnosis, connect with the right specialists, manage insurance approvals, prepare for treatment, and avoid the ER when an issue can be handled at home. The company calls itself a virtual oncology navigation platform. The industry is starting to call it a blueprint.
The round was led by Morgan Health, JPMorgan Chase's healthcare innovation arm, with participati…
